Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer (NCT04754425) | M.D. Anderson Cancer Center | 2021-07-15 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04033432) | Northwestern University | 2019-09-20 |
Track Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents automatically
Every clearance here is in the API, with alerts when new ones post.